Entering text into the input field will update the search result below

Regeneron and Kiniksa sign commercial supply agreement for Rilonacept

  • Kiniksa Pharmaceuticals (NASDAQ:KNSA) has announced a commercial supply agreement with Regeneron (NASDAQ:REGN) giving the latter the exclusive right to manufacture and supply rilonacept for Kiniksa’s U.K. subsidiary.
  • The two companies had entered into a license agreement in September 2017 with Kiniksa having

Recommended For You

Related Stocks

SymbolLast Price% Chg
REGN
--
KNSA
--